Glenmark Pharmaceuticals (NSE:GLENMARK, BOM:532296) unit Glenmark Specialty obtained approval from the U.S. Food and Drug Administration for the expanded use of Ryaltris nasal spray, according to a Tuesday Indian bourse filing.
The nasal spray has been approved for the treatment of seasonal allergic rhinitis in pediatric patients older than six years of age and younger than 12.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments